Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease.
The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers.
It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug.
Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 24, 25 | -0.62 Decreased by -121.43% | -0.37 Decreased by -69.49% |
| Nov 13, 24 | -0.50 Decreased by -106.42% | -0.36 Decreased by -37.61% |
| Aug 13, 24 | -0.34 Decreased by -21.43% | -0.28 Decreased by -21.43% |
| May 14, 24 | -0.25 Increased by +10.71% | -0.26 Increased by +3.85% |
| Mar 26, 24 | -0.28 Increased by +12.50% | -0.26 Decreased by -7.69% |
| Nov 13, 23 | -0.24 Increased by +7.69% | -0.27 Increased by +11.11% |
| Aug 8, 23 | -0.28 Decreased by -12.00% | -0.35 Increased by +20.00% |
| May 9, 23 | -0.28 Decreased by -21.74% | -0.35 Increased by +20.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -37.15 M Decreased by -125.22% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -29.77 M Decreased by -129.72% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -20.54 M Decreased by -76.89% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -14.87 M Decreased by -56.90% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 290.00 K Increased by +N/A% | -16.50 M Decreased by -18.99% | Decreased by -5.69 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -12.96 M Decreased by -28.94% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -11.61 M Decreased by -17.38% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -9.48 M Decreased by -4.72% | Decreased by N/A% Decreased by N/A% |